A Bruchfeld

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    Ther Drug Monit 24:701-8. 2002
  2. ncbi Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study
    A Bruchfeld
    Division of Renal Medicine, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    J Viral Hepat 8:287-92. 2001
  3. ncbi Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Karolinska Institute and Huddinge University Hospital, S 141 86 Stockholm, Sweden
    Nephrol Dial Transplant 18:1573-80. 2003
  4. ncbi Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Center for Surgical Sciences, Karolinska Institute and Huddinge University Hospital, 141 86 Stockholm, Sweden
    Transplantation 78:745-50. 2004
  5. ncbi Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients
    A Bruchfeld
    Department of Renal Medicine, Karolinska University Hospital Huddinge and Solna, Karolinska Institute, Stockholm, Sweden
    J Viral Hepat 13:316-21. 2006
  6. ncbi Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia
    K Lindahl
    Division of Infectious Diseases, Department of Medicine, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    J Viral Hepat 11:84-7. 2004
  7. ncbi Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients
    M Wendt
    Division of Renal Medicine, Karolinska University Hospital, CLINTEC, Karolinska Institute, Stockholm, Sweden
    Scand J Rheumatol 41:116-9. 2012
  8. ncbi High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C
    Karin Lindahl
    Department of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Hepatology 41:275-9. 2005
  9. ncbi Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia--anti-viral therapy vs rituximab
    Annette Bruchfeld
    Rheumatology (Oxford) 45:783-4; author reply 784-5. 2006
  10. ncbi High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD)
    Annette Bruchfeld
    Feinstein Institute for Medical Research, North Shore University Hospital LIJ Health System, Manhasset, New York, USA
    Mol Med 14:109-15. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    Ther Drug Monit 24:701-8. 2002
    ..Ribavirin monitoring may be useful for optimizing HCV treatment not only in patients with renal insufficiency but also in other patients considering the time to steady state and the interindividual variability in ribavirin clearance...
  2. ncbi Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study
    A Bruchfeld
    Division of Renal Medicine, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    J Viral Hepat 8:287-92. 2001
    ..However, this requires reduced ribavirin doses and close monitoring of ribavirin plasma concentrations and haemoglobin. Ribavirin-induced anaemia can be managed with high doses of erythropoeitin...
  3. ncbi Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Karolinska Institute and Huddinge University Hospital, S 141 86 Stockholm, Sweden
    Nephrol Dial Transplant 18:1573-80. 2003
    ..Standard treatment for HCV is interferon and ribavirin, but in renal insufficiency ribavirin has been contraindicated due to fear of side effects...
  4. ncbi Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation
    Annette Bruchfeld
    Division of Renal Medicine, Department of Clinical Science, Center for Surgical Sciences, Karolinska Institute and Huddinge University Hospital, 141 86 Stockholm, Sweden
    Transplantation 78:745-50. 2004
    ..The aim of this study was to investigate HCV in relation to time in RRT and its impact on outcome after transplantation...
  5. ncbi Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients
    A Bruchfeld
    Department of Renal Medicine, Karolinska University Hospital Huddinge and Solna, Karolinska Institute, Stockholm, Sweden
    J Viral Hepat 13:316-21. 2006
    ..However the pharmacokinetics and tolerability of both peg-alfa-2a and 2b need to be studied more closely in prospective studies before definite dosing recommendations can be made...
  6. ncbi Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia
    K Lindahl
    Division of Infectious Diseases, Department of Medicine, Karolinska Institute and Huddinge University Hospital, Stockholm, Sweden
    J Viral Hepat 11:84-7. 2004
    ..This lends further support to the idea that ribavirin should be dosed according to renal function...
  7. ncbi Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients
    M Wendt
    Division of Renal Medicine, Karolinska University Hospital, CLINTEC, Karolinska Institute, Stockholm, Sweden
    Scand J Rheumatol 41:116-9. 2012
    ..Rituximab, a chimeric anti-CD20 antibody, has emerged as a second-line therapy, although controlled studies are scarce in patients with relapsing or refractory disease...
  8. ncbi High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C
    Karin Lindahl
    Department of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Hepatology 41:275-9. 2005
    ..In conclusion, a high dose of ribavirin according to an individualized schedule is feasible but associated with more frequent and serious side effects such as anemia. The viral response merits further evaluation...
  9. ncbi Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia--anti-viral therapy vs rituximab
    Annette Bruchfeld
    Rheumatology (Oxford) 45:783-4; author reply 784-5. 2006
  10. ncbi High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD)
    Annette Bruchfeld
    Feinstein Institute for Medical Research, North Shore University Hospital LIJ Health System, Manhasset, New York, USA
    Mol Med 14:109-15. 2008
    ..Future studies may delineate whether HMGB-1 is also a marker of disease activity and severity as well as a predictor of outcome in CKD...
  11. ncbi The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients
    Marcelo M Nascimento

    Nephrol Dial Transplant 19:3112-6. 2004
    ..CONCLUSION: HCV in HD patients is associated with increased pentosidine levels, possibly reflecting increased oxidative stress. The association between pentosidine and ferritin levels may suggest an impact of i.v. iron therapy...